Opal Wealth Advisors LLC Has $267,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Opal Wealth Advisors LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 11.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,061 shares of the biopharmaceutical company’s stock after buying an additional 1,072 shares during the period. Opal Wealth Advisors LLC’s holdings in Pfizer were worth $267,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Ritholtz Wealth Management lifted its stake in shares of Pfizer by 26.3% in the third quarter. Ritholtz Wealth Management now owns 55,267 shares of the biopharmaceutical company’s stock valued at $1,599,000 after buying an additional 11,519 shares during the period. Retirement Planning Group LLC bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $354,000. Exchange Traded Concepts LLC increased its position in shares of Pfizer by 117.0% during the third quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock valued at $2,002,000 after purchasing an additional 37,293 shares during the period. Essex Investment Management Co. LLC acquired a new stake in Pfizer during the third quarter worth $4,370,000. Finally, McGlone Suttner Wealth Management Inc. increased its holdings in Pfizer by 17.7% in the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 15,378 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 2,311 shares during the period. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 0.3 %

PFE stock opened at $25.76 on Monday. The business has a fifty day moving average of $26.28 and a 200-day moving average of $27.73. The company has a market cap of $145.96 billion, a P/E ratio of 18.27, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company posted $0.10 EPS. The company’s revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.68%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.